Injections, Subcutaneous

"Injections, Subcutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.

Descriptor ID	D007279
MeSH Number(s)	E02.319.267.530.620
Concept/Terms	Injections, Subcutaneous Injections, Subcutaneous Subcutaneous Injections Injection, Subcutaneous Subcutaneous Injection

Below are MeSH descriptors whose meaning is more general than "Injections, Subcutaneous".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Administration Routes [E02.319.267]
Injections [E02.319.267.530]
Injections, Subcutaneous [E02.319.267.530.620]

Below are MeSH descriptors whose meaning is related to "Injections, Subcutaneous".

Below are MeSH descriptors whose meaning is more specific than "Injections, Subcutaneous".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Injections, Subcutaneous" by people in this website by year, and whether "Injections, Subcutaneous" was a major or minor topic of these publications.

Bar chart showing 104 publications over 28 distinct years, with a maximum of 10 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	4	4
1997	0	1	1
1998	0	1	1
1999	0	2	2
2000	0	4	4
2001	0	3	3
2002	0	2	2
2003	0	1	1
2004	0	2	2
2005	0	4	4
2006	0	9	9
2007	0	2	2
2008	0	4	4
2009	0	2	2
2010	0	3	3
2011	0	5	5
2012	2	2	4
2013	0	2	2
2014	0	3	3
2015	0	5	5
2016	0	3	3
2017	0	6	6
2018	0	10	10
2019	1	7	8
2020	0	5	5
2021	0	2	2
2022	0	2	2
2024	0	5	5

Below are the most recent publications written about "Injections, Subcutaneous" by people in Profiles.

Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Kr?ger N, Tabori S, Sch?kel K. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024 Sep 01; 160(9):953-963.

View in: PubMed
Marous CL, Wladis EJ. Reply Re: "Effects of Preoperative Intravenous Versus Subcutaneous Tranexamic Acid on Postoperative Periorbital Ecchymosis and Edema Following Upper Eyelid Blepharoplasty: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Comparative Study". Ophthalmic Plast Reconstr Surg. 2024 Jul-Aug 01; 40(4):471.

View in: PubMed
Sannala CKR, MacLean C, Larsen F, van Os S, Jadhav P, Shore N, Morgans AK, Okwuosa T, Gobburu J. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. Clin Pharmacol Drug Dev. 2024 Aug; 13(8):915-929.

View in: PubMed
Klein K, Klein KO, Miller BS, Mauras N. Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical Response. Horm Res Paediatr. 2025; 98(5):514-523.

View in: PubMed
Marous CL, Farhat OJ, Cefalu M, Rothschild MI, Alapati S, Wladis EJ. Effects of Preoperative Intravenous Versus Subcutaneous Tranexamic Acid on Postoperative Periorbital Ecchymosis and Edema Following Upper Eyelid Blepharoplasty: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Comparative Study. Ophthalmic Plast Reconstr Surg. 2024 Sep-Oct 01; 40(5):523-532.

View in: PubMed
Ashina M, Goadsby PJ, Dodick DW, Tepper SJ, Xue F, Zhang F, Brennan F, Paiva da Silva Lima G. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA Neurol. 2022 02 01; 79(2):159-168.

View in: PubMed
Kyrillos JV, O'Neil PM, Wharton S. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgrad Med. 2022 01; 134(sup1):1-4.

View in: PubMed
Hebert KJ, Findlay BL, Yang DY, Houlihan MD, Bole R, Avant RA, Andrews JR, Jimbo M, Ziegelmann MJ, Helo S, K?hler TS. Incidence of Venous Thromboembolism and Safety of Perioperative Subcutaneous Heparin During Inflatable Penile Prosthesis Surgery. Urology. 2021 11; 157:155-160.

View in: PubMed
Sasipong N, Schlegel P, Wingert J, Lederer C, Meinhardt E, Ziefer A, Schmidt C, Rapti K, Th?ni C, Frey N, Most P, Katus HA, Raake PWJ. Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction. Mol Ther. 2021 08 04; 29(8):2499-2513.

View in: PubMed
Norris MR, Khaimov M, Bielory L. Use of allergen immunotherapy for treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2020 12; 20(6):609-615.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement